Pre-Market Scans on Biotech Stocks - Sarepta Therapeutics, Medivation, Alexion Pharma, Alkermes, and Cepheid
PR Newswire - Tue Dec 23, 7:50AM CST
Investor-Edge has initiated coverage on the following equities: Sarepta Therapeutics Inc. (NASDAQ: SRPT), Medivation Inc. (NASDAQ: MDVN), Alexion Pharmaceuticals Inc. (NASDAQ: ALXN), Alkermes PLC (NASDAQ: ALKS), and Cepheid (NASDAQ: CPHD). Free research on these five companies can be accessed at: http://investor-edge.com/register. On Monday, December 22, 2014, the NASDAQ Composite ended at 4,781.42, up 0.34%, the Dow Jones Industrial Average advanced 0.87%, to finish the day at 17,959.44, and the S&P 500 closed at 2,078.54, up 0.38%. The gains were broad based as eight out of ten sectors ended the session in positive. The S&P 500 Health Care Sector Index ended the day at 807.53, down 1.15%, while the index has advanced 8.06% in the previous three months. Register for your complimentary reports on these five stocks at:
MDVN: 99.23 (+1.23), SRPT: 13.88 (+0.47), CPHD: 53.39 (+0.51), ALXN: 181.96 (+3.09), ALKS: 56.16 (+1.02)
Upgrade Alert for Cepheid (CPHD)
Comtex SmarTrend(R) - Thu Dec 18, 7:13AM CST
Cepheid (NASDAQ:CPHD) was upgraded from Neutral to Buy at BofA/Merrill today. The stock closed yesterday at $49.79 on volume of 872,000 shares, above average daily volume of 525,000. Cepheid has overhead space with shares priced $49.79, or 7.0% below the average consensus analyst price target of $53.55. The stock should hit resistance at its 50-day moving average (MA) of $50.64, as well as support at its 200-day MA of $46.34.
CPHD: 53.39 (+0.51)
Medical Diagnostics, Reagents, Assays and Test Kits Manufacturing Industry (U.S.): Analytics, Extensive Financial Benchmarks, Metrics and Revenue Forecasts to 2021
M2 - Mon Dec 15, 8:07AM CST
Research and Markets (http://www.researchandmarkets.com/research/267psb/medical) has announced the addition of Plunkett Research Ltd's new report "Medical Diagnostics, Reagents, Assays and Test Kits Manufacturing Industry (U.S.): Analytics, Extensive Financial Benchmarks, Metrics and Revenue Forecasts to 2021" to their offering. Medical Diagnostics, Reagents, Assays and Test Kits Manufacturing Industry (U.S.) to reach $19.2 billion by 2021. Vital industry-specific data including metrics, benchmarks, historic numbers, growth rates and forecasts that will save countless hours of research. This Report Features: 1. Historical data 2. Revenue forecasts, growth rates and CAGR 3. Operating ratios 4. Complete data for benchmarking a company to its industry and to specific leading companies 5. Benchmarking this industry to all U.S. industries 6. Deep profiles and financial histories/operating ratios for up to ten top U.S.-based companies Designed to benefit: - Analysis and Financial Modeling - Investment Professionals - Lenders - M&A Advisors - Appraisers - Consultants Key Data: Industry Summary - Revenues historical through 2013 - Revenues projected through 2021 - Employee Count 2007-2013 - Annual Growth Rate 2013 - CAGR 2006 through 2013 - CAGR 2014 through 2021 - Top U.S. Companies Employment and Establishments - Number of Firms 2007-2013 - Number of Establishments 2007-2013 - Employees, 2007-2013 - Average Annual Sales per Firm & per Establishment 2007-2013 - Sales per Employee Average Annual Operating Ratios - Revenue Compared to All Industries - Expenses Compared to All Industries - Profits & Income Taxes Compared to All Industries Benchmarks This Industry Compared to All Industries - Comparison of Revenues, Profits and Taxes to All Industries Industry Results, Publicly-Held Companies (U.S.), Average for all Companies - Industry Income Statement, Balance Sheet, Cash Flow Statement, 2008-2013 Top Companies Profiled & Ranked In-Depth Profiles, Financial Reports, Ranks & Executive Lists for Top U.S.-Based Corporations Top Companies Ranked - Market Capitalization - Employees - Revenue - Net Income - 3-Year Revenue Growth - 3-Year Income Growth - Return on Assets - Return on Equity - Return on Invested Capital List of Leading (Public and Private) Companies Comparison of Individual Top Publicly-Held Companies to Industry Averages, 2013 - Income Statements. Balance Sheets and Cash Flow Statements Companies Mentioned - Alere Inc - Bio Rad Laboratories Inc - Cepheid - Hologic GenProbe Inc - Hologic Inc - Illumina Inc - Immucor Inc - Life Technologies Corp - PerkinElmer Inc - Promega Corp For more information visit http://www.researchandmarkets.com/research/267psb/medical Source: Plunkett Research Ltd
CPHD: 53.39 (+0.51), ILMN: 186.22 (+2.72), ALR: 37.48 (+0.37), PKI: 43.99 (-0.06), HOLX: 26.89 (+0.10)
26.3% Return Seen to Date on SmarTrend Cepheid Call (CPHD)
Comtex SmarTrend(R) - Wed Dec 10, 9:13AM CST
SmarTrend identified an Uptrend for Cepheid (NASDAQ:CPHD) on September 5th, 2014 at $41.51. In approximately 3 months, Cepheid has returned 26.27% as of today's recent price of $52.41.
CPHD: 53.39 (+0.51)
2014-2018 US Molecular Diagnostics Market: Sales and Market Shares of Major Suppliers
M2 - Mon Dec 08, 8:27AM CST
Research and Markets (http://www.researchandmarkets.com/research/vf9r39/20142018_us) has announced the addition of the "2014-2018 US Molecular Diagnostics Market: Sales and Market Shares of Major Suppliers" report to their offering. This unique report provides US sales and market share estimates for major suppliers of molecular diagnostic products. The report also presents strategic assessments of major suppliers and emerging market entrants, including their product portfolios, marketing tactics, technological know-how, new products in R&D, collaborative arrangements, and business strategies. Competitive Assessments - Abbott - Affymetrix - Agilent Technologies - Applied Gene Technologies - Beckman Coulter/Danaher - Becton Dickinson - Biokit - BioMerieux - Bio-Rad - Biotest - Caliper - Cepheid - Decode - Diadexus - Eiken - Enzo - Exact Sciences - Grifols - Illumina - Kreatech - Li-Cor Biosciences - Life Technologies/Thermo Fisher - Monogram Biosciences - Myriad Genetics - Ortho-Clinical Diagnostics - Proteome Sciences - Qiagen - Roche - Takara Bio - Tecan Group For more information visit http://www.researchandmarkets.com/research/vf...0142018_us
MYGN: 36.50 (+0.28), A: 41.13 (-0.24), CPHD: 53.39 (+0.51), DHR: 86.79 (-0.27)
Global Sexually Transmitted Diseases (STDs) Testing Market 2013-2020 Disease Types, Testing Volume & Testing Devices Analysis of the $167 Billion Industry
M2 - Wed Dec 03, 8:44AM CST
Research and Markets (http://www.researchandmarkets.com/research/trmsj7/global_sexually) has announced the addition of the "Global Sexually Transmitted Diseases (STDs) Testing Market (Disease Types, Testing Volume, Testing Devices and Geography) - Industry Analysis and Forecast, 2013 - 2020" report to their offering. The diagnostic testing market for sexually transmitted diseases is forecast to reach $167.4 billion by 2020, registering a CAGR of 8.5% during 2014-2020 The growth in the market is chiefly attributed to the high growth in HIV and HPV testing, especially in Asia Pacificand African regions along with complimenting growth rate of the European market. Laboratory testing of STDs is significant, despite of the presence of many point-of-care (PoC) testing kits available. Some of the STDs are not diagnosed with point of care methods. For instance, HSV (Herpes Simplex Virus), low-risk HPV (Human Papilloma Virus) and Chancroid that manifest as 'warts' on the patient's skin, require physical examination by the laboratory experts. Also, many of the PoC devices are not yet approved by the regulatory health authorities such as USFDA, owing to deviations in the sensitivity and specificity criteria. For these reasons, laboratory testing is considered to be most reliable and globally accepted method for STD testing; therefore, garners a comparatively larger market share than POC testing. The report also provides market size and forecast for testing devices used for carrying such tests. The market for STD testing devices was valued at $7.7 billion in 2013 with laboratory testing devices accounted for the most of the market and PoC devices shall grow at fastest rate. Key findings of the study: - Global market for diagnostic testing of STDs is gaining traction with growth in HIV and HPV screening and laboratory testing - HIV testing market segment would grow at a CAGR of 10.9% during the forecast period - Europe would be one of the lucrative markets in terms of growth. The European STDs testing market would reach $26.8 billion by 2020, with highest CAGR of 13.5% (as compared to other regional markets) - HPV testing volume and revenue will grow at much faster rate owing to higher incidences in Asia Pacific region Scope of the Report MARKET BY SEXUALLY TRANSMITTED DISEASE TYPES - Chlamydia testing - Syphilis testing - Gonorrhoea testing - Herpes Simplex Virus testing - Human Papilloma Virus testing - Human Immunodeficiency Virus testing - Chancroid testing MARKET BY LOCATION OF TESTING Laboratory Testing - Commercial/Private labs - Public Health Labs Point of Care (PoC) testing MARKET BY TESTING DEVICES Laboratory Devices: Instruments and systems - Thermal Cyclers - PCR - Lateral Flow Readers - Immunochromatographic assays - Flow Cytometers - Differential Light Scattering machines - Absorbance microplate reader - Enzyme Linked Immunosorbent Assay (ELISA) POC testing Devices: Various diagnostic kits - Phone chips (microfluidics ICT) - Portable / bench top / rapid diagnostic kits Companies Mentioned - Abbott Laboratories - Affymetrix, Inc. - Alere, Inc. - Becton Dickinson & Company - BioMerieux - Cepheid, Inc. - Danaher Corporation - DiaSorin - Hologic, Inc. - Roche Diagnostics For more information visit http://www.researchandmarkets.com/research/tr...l_sexually
ABT: 45.70 (-0.02), BDX: 139.90 (+1.44), CPHD: 53.39 (+0.51), DHR: 86.79 (-0.27), ALR: 37.48 (+0.37), HOLX: 26.89 (+0.10), AFFX: 9.80 (+0.05)
Top Medical Stocks: Cepheid Diagnostics Sales Strong
at Investor's Business Daily - Tue Dec 02, 4:48PM CST
Cepheid (CPHD) has performed well since reporting third-quarter results on Oct. 16. Following the report the stock gapped higher and regained its 200-day moving average for the first time in three months. On Oct. 27, the stock cleared a 50.56 buy...
CPHD: 53.39 (+0.51)
Shares of CPHD Up 29.2% Since Uptrend Call on Shares
Comtex SmarTrend(R) - Tue Dec 02, 4:47PM CST
SmarTrend identified an Uptrend for Cepheid (NASDAQ:CPHD) on September 5th, 2014 at $41.51. In approximately 3 months, Cepheid has returned 29.15% as of today's recent price of $53.61.
CPHD: 53.39 (+0.51)
Cepheid Wins FDA Clearance for Xpert Norovirus Test - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Dec 02, 1:40PM CST
Cepheid's (CPHD) Xpert Norovirus test comes as the much-desired solution, with its capacity to determine the presence of Norovirus and accurately isolate the different groups of this pathogen
ETRM: 1.40 (-0.01), FLDM: 32.31 (+0.30), CPHD: 53.39 (+0.51), ANGO: 19.19 (+0.33)
Cepheid Receives FDA Clearance for Xpert Norovirus, the First On-Demand Molecular Test for Detection of Norovirus
PR Newswire - Mon Dec 01, 6:00AM CST
Cepheid (NASDAQ: CPHD) today announced it has received clearance from the U.S. Food & Drug Administration (FDA) to market Xpert® Norovirus, a qualitative in vitro diagnostic test for expeditious identification and differentiation of Noroviruses genogroup I (GI) and genogroup II (GII). Both Xpert Norovirus and the recently cleared Xpert Flu/RSV XC have also been categorized as Moderate Complexity tests. All Xpert tests run on Cepheid's GeneXpert® System, the world's leading molecular diagnostic platform with more than 7,500 systems installed worldwide.
CPHD: 53.39 (+0.51)
Cepheid, FIND & Rutgers Announce Collaboration for Next-Generation Innovations to Game-changing Xpert MTB/RIF Test
PR Newswire Europe - Wed Nov 26, 7:10PM CST
Cepheid , FIND, and Rutgers New Jersey Medical School, today announced details of a collaboration to develop Xpert((R)) MTB/RIF Ultra, a next-generation test for Mycobacterium tuberculosis (TB) with increased sensitivity to aid in detection of patients with smear-negative TB, which is often associated with HIV co-infection. The collaboration is also receiving additional support from the National Institute of Allergy and Infectious Diseases at the NIH(1).
CPHD: 53.39 (+0.51)
Cepheid Gets FDA Clearance for Xpert Flu/RSV XC Test - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Nov 25, 1:50PM CST
Cepheid's (CPHD) Xpert Flu/RSV XC test can accurately detect the presence of Flu A, Flu B as well as respiratory syncytial virus (RSV) infection in a patient's body.
ETRM: 1.40 (-0.01), FLDM: 32.31 (+0.30), CPHD: 53.39 (+0.51), ANGO: 19.19 (+0.33)
Shares of CPHD Up 30.8% Since Uptrend Call on Shares
Comtex SmarTrend(R) - Tue Nov 25, 10:59AM CST
SmarTrend identified an Uptrend for Cepheid (NASDAQ:CPHD) on September 5th, 2014 at $41.51. In approximately 3 months, Cepheid has returned 30.84% as of today's recent price of $54.31.
CPHD: 53.39 (+0.51)
CEPHEID
at Investor's Business Daily - Mon Nov 24, 5:43PM CST
CEPHEID (CPHD) received FDA clearance to market its Xpert Flu/RSV XC, a flu differentiation test. Shares were unchanged .
CPHD: 53.39 (+0.51)
Cepheid Receives FDA Clearance for Xpert Flu/RSV XC
PR Newswire - Mon Nov 24, 3:05PM CST
Cepheid (NASDAQ: CPHD) today announced it has received clearance from the U.S. Food & Drug Administration (FDA) to market its Xpert® Flu/RSV XC, an on-demand molecular test for accurate and reliable determination of Flu A, Flu B, and differentiation of RSV infection. Xpert Flu/RSV XC runs on Cepheid's GeneXpert® System, the world's leading molecular diagnostic platform with more than 7,500 systems installed worldwide.
CPHD: 53.39 (+0.51)
2014-2014 UK Hepatitis Markers Testing Market: Hospitals, Blood Banks, Public Health Labs, Commercial Labs--Supplier Shares and Sales Forecasts For 10 Immunodiagnostic and NAT Procedures
M2 - Mon Nov 24, 10:25AM CST
Research and Markets (http://www.researchandmarkets.com/research/swvhm8/20142014_uk) has announced the addition of the "2014-2014 UK Hepatitis Markers Testing Market: Hospitals, Blood Banks, Public Health Labs, Commercial Labs--Supplier Shares and Sales Forecasts For 10 Immunodiagnostic and NAT Procedures" report to their offering. The report presents a detailed analysis of the Hepatitis diagnostics market in the UK. Current scientific views on the Hepatitis definition, epidemiology and etiology are reviewed. The report provides five-year test volume and sales forecasts for HAV NAT, HBV NAT, HBs Ag, HCV, Anti-HBc, Anti-HBs, Anti-HAV, Hepatitis Delta, HBc Ag, HBe Ag, and ALT/SGPT tests performed in the following markets: - Hospitals - Commercial/Private Labs - Blood Banks In addition to test volume and sales projections, the report presents sales and market share estimates for major suppliers of Hepatitis tests. Also, the report examines the market applications of DNA Probes, Monoclonal Antibodies, Immunoassays, IT and other technologies; reviews features and operating characteristics of automated analyzers; profiles leading suppliers and recent market entrants developing innovative technologies and products; and identifies emerging business expansion opportunities, alternative market penetration strategies, market entry barriers and risks, and strategic planning issues and concerns. Key Topics Covered: - INTRODUCTION - HEPATITIS WORLDWIDE MARKET AND TECHNOLOGY OVERVIEW - UK: MARKET SIZE, GROWTH AND MAJOR SUPPLIERS' SALES AND MARKET SHARES - POTENTIAL MARKET ENTRY BARRIERS AND RISKS - COMPETITIVE ASSESSMENTS - Abbott - Affymetrix - Beckman Coulter/Danaher - Becton Dickinson - bioMerieux - Bio-Rad - Cepheid - Diamedix - DiaSorin - Eiken Chemical - Enzo Biochem - Fujirebio/Innogenetics - Hologic/Gen-Probe - ID Biomedical/GSK - Kreatech - Life Technology - Lonza - Nanogen/Elitech - Novartis Diagnostics/Grifols - Ortho-Clinical Diagnostics - Qiagen - Roche - Scienion - Sequenom - SeraCare - Siemens - Takara Bio - Thermo Fisher - Wallac/PE - Wako For more information visit http://www.researchandmarkets.com/research/sw...0142014_uk
SQNM: 3.59 (-0.01), ENZ: 4.51 (+0.09), CPHD: 53.39 (+0.51), DHR: 86.79 (-0.27), HOLX: 26.89 (+0.10), NVS: 93.91 (+0.66)
Cepheid to Webcast Upcoming Financial Presentations
PR Newswire - Thu Nov 20, 3:05PM CST
Cepheid (NASDAQ: CPHD) today announced that its executives will be speaking at the following conferences, and invited investors to participate via webcast.
CPHD: 53.39 (+0.51)
Molecular Diagnostics in Infectious Disease Testing 2014
M2 - Thu Nov 20, 9:01AM CST
Research and Markets (http://www.researchandmarkets.com/research/zbf7zn/molecular) has announced the addition of the "Molecular Diagnostics in Infectious Disease Testing 2014" report to their offering. This publications report describes the specific segment of the in vitro diagnostics market known as molecular diagnostics testing for infectious disease. In the current medical diagnostics market, molecular diagnostics in infectious disease testing offers one of the most promising areas for growth and innovation. The confluence of breakthroughs in genomics and proteomics-along with the development of microarray devices to measure analytes in the blood-has led to this revolutionary market development. Specifically, molecular diagnostics offers the power of advanced analytical techniques to diagnose infectious diseases. Whereas before, the detection of many infectious agents was slow and expensive due to reliance upon culturing methods, researchers are now at the cusp of overcoming such limitations via the use of nucleic acid-mediated molecular diagnostics testing. The purpose of this report is to describe the emerging field of molecular diagnostics in infectious disease testing. The infectious disease space is the most dominant and profitable sector of molecular diagnostics. Topics covered in this study include: 1) the existing and emerging technologies in the field, 2) the U.S. and global market size for molecular diagnostic products and 3) the profiles of companies that are focusing on the molecular diagnostic sector. The research examines drivers and restraints for sales growth, market share and technical trends. In addition, an in-depth analysis of the competitive situation of prominent market venders is provided with five-year sales forecasts. Key Topics Covered: 1. Overview 2. Introduction to Molecular Diagnostics for Infectious Disease Testing 3. Infectious Disease Diagnostics Molecular Testing Market 4. Molecular Diagnostic Testing Technology for Infectious Disease Testing 5. Business 6. Reimbursement and Billing Landscape for Molecular Diagnostics Testing for Infectious Disease 7. Regulatory Requirements 8. Business Decisions using Molecular Diagnostic Tests in Infectious Disease Testing 9. Economics of Anti-Microbial Drug Resistance: The Persistent Need for Antibacterials 10. Company Profiles - Abbott Laboratories - AdvanDx - Affymetrix - Arcxis Biotechnologies - Asuragen, Inc. - AutoGenomics, Inc. - Becton, Dickinson and Company - bioM?rieux - Biocartis - BioHelix Corporation (now part of Quidel) - bioTheranostics - Cepheid - EraGen Biosciences - GenMark Diagnostics, Inc. - Genomix Biotech - Gen-Probe, Inc. (now known as Hologic Gen-Probe) - Genomica S.A.U. - Great Basin Corporation - Illumina, Inc. - Life Technologies (Thermo Fisher Scientific) - Luminex Corp. - Mobidiag - Myconostica - Myriad Genetics, Inc. - Nanosphere - NorDiag ASA (The DiaSorin Group) - Qiagen N.V. - Quidel - Roche Diagnostics (Roche Ltd.) - SACACE For more information visit http://www.researchandmarkets.com/research/zbf7zn/molecular
GNMK: 13.67 (+0.06), ABT: 45.70 (-0.02), MYGN: 36.50 (+0.28), CPHD: 53.39 (+0.51), ILMN: 186.22 (+2.72), QGEN: 23.20 (+0.09), LMNX: 18.60 (+0.37)
Cepheid Has Returned 27.7% Since SmarTrend Recommendation (CPHD)
Comtex SmarTrend(R) - Tue Nov 18, 9:38AM CST
SmarTrend identified an Uptrend for Cepheid (NASDAQ:CPHD) on September 5th, 2014 at $41.51. In approximately 2 months, Cepheid has returned 27.74% as of today's recent price of $53.02.
CPHD: 53.39 (+0.51)
Cepheid Shines in Global Market, Raises Revenue Outlook - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Nov 13, 2:00PM CST
Cepheid (CPHD) now expects total revenue for 2014 in the range of $461???$465 million, higher than the earlier range of $452???$461 million.
ACHC: 62.92 (+0.34), AFAM: 29.53 (-0.06), ADHD: 4.00 (+0.24), CPHD: 53.39 (+0.51)